For Research Use Only · Not For Human or Veterinary Use · Not FDA-Approved
A sealed Merit Tesamorelin vial, 20 mg of lyophilized research compound
Independently assayed · HPLC ≥99%

Tesamorelin 20 mg

Lyophilized vial · 44 AA

— Vial size

10 mg$86.9920 mg$149.99
$149.99

Per vial

Select your pack size

Single

Ships within 48 hours from San Antonio

UPS Ground · tracked + insured · released after independent lab testing

  • Purity Guarantee. If a batch fails our ≥99% HPLC standard, full refund + replacement.
  • Batch certificate in the COA library, anytime, free
  • Same reorder price — forever, no upcharge

$149.99

Single

Independently assayedLicensed US facilitySan Antonio, TX

Tesamorelin in brief

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH), studied in research on visceral adipose tissue. Tesamorelin is FDA-approved only as specific branded prescription drug products; research material sold as tesamorelin is not one of those products and is not FDA-approved. Supplied for research use only.

Independently Assayed≥99% PurityIndependently Assayed · Licensed US Facility48hr Dispatch from San Antonio

— About this compound

Tesamorelin.

Class · Stabilized GHRH(1-44) analog with trans-3-hexenoic acid N-terminal modification

Origin. Developed by Theratechnologies. Approved by the FDA in 2010 (brand name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — one of the few approved peptide therapeutics in this class.

Tesamorelin is a synthetic 44-amino-acid analog of human GHRH carrying a trans-3-hexenoic acid moiety at the N-terminus. This modification stabilizes the peptide against dipeptidyl peptidase IV (DPP-IV) cleavage, substantially extending plasma half-life relative to native GHRH and to sermorelin.

The compound is the most clinically validated GHRH analog in research literature, having been studied in multiple multicenter randomized trials in HIV-associated lipodystrophy and, more recently, NAFLD.

— Common research applications

  • GHRH receptor pharmacology
  • HIV-lipodystrophy research
  • Hepatic steatosis investigation
  • Visceral adipose tissue studies

— Mechanism

How it's been studied.

Selective agonist at pituitary GHRH receptors. The trans-hexenoic acid modification confers DPP-IV resistance, producing longer duration of GHRH-receptor activation per dose. Downstream effects are mediated by pulsatile GH release and consequent IGF-1 generation.

Mechanism descriptions reflect findings reported in the preclinical and basic-research literature. They are not clinical conclusions and not statements of therapeutic effect.

— The Chemistry

The numbers, plainly.

CAS

218949-48-5

Molecular weight

5135.9 Da

Formula

—

Sequence

—

Format

Lyophilized powder

Vial dose

20 mg

Purity (HPLC)

≥99%

Amino acids

44

Half-life

~25–40 min (subcutaneous administration in clinical studies).

Solubility

Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.

View the July 2026 batch certificate for Tesamorelin 20 mg → or browse every certificate.

— Why Merit

The supplier difference.

How Merit compares to the two alternatives most research buyers consider for Tesamorelin.

Criterion
MeritLicensed US facility
Online ResellersRUO only
Compounding RxRx required
HPLC chromatogram per batch
sometimes
on request
Independent assay before release
QR code on the vial label opens the COA library
rarely
Ships from a licensed US facility
varies
Same reorder price — no markup over time
varies
48-hour dispatch

Comparison reflects published facility status and standard industry practice. Compounding pharmacy availability of research peptides varies by jurisdiction.

— How it's made

From compound to your shelf.

Every Merit batch follows the same documented path. Five steps, every one verifiable.

  1. 01

    Sourcing

    Compound starts as a research-grade API.

    Active pharmaceutical ingredient sourced from FDA-registered manufacturers. Identity confirmed against reference standard before any compounding begins.

    • API from FDA-registered manufacturers
    • Identity verified against reference standard
    • Chain of custody documented
  2. 02

    Compounding

    Sterile-filled in a US cleanroom.

    Lyophilized in a cleanroom at our US facility. The powder format gives ≥24 months sealed stability — no cold-chain shipping required.

    • Licensed US facility
    • Batch-documented manufacturing process
    • Lyophilized powder for transit stability
  3. 03

    Verification

    Every batch HPLC-tested.

    Reverse-phase HPLC-UV (UV/MS for higher-MW peptides) confirms identity and purity for every batch before it leaves the lab. The chromatogram is archived.

    • Reverse-phase HPLC, per-batch
    • ≥99% purity floor — every batch
    • Chromatogram archived for every batch
  4. 04

    Release

    The batch is released against an independent assay.

    No batch ships until an independent laboratory has returned its identity and purity results and the certificate is published in the COA library.

    • Independent laboratory on every batch
    • Certificate published before sale
    • Every certificate is in the public COA library
  5. 05

    Dispatch

    Ships from San Antonio in 48 hours.

    Sealed vials with a QR code on the label that opens the COA library. Order before 2pm CT Monday–Thursday for same-day dispatch. UPS Ground, tracked + insured.

    • 48hr dispatch from San Antonio, TX
    • QR code on every vial label
    • UPS Ground, tracked + insured

Every step above can be verified for any specific batch by emailing support@meritsciences.com with your order number.

— Research references

The published record.

Peer-reviewed work cited in the public scientific literature. Links resolve to PubMed or the publisher of record.

  1. 01

    Metabolic effects of a growth hormone-releasing factor in patients with HIV

    Falutz J, Allas S, Blot K, et al. · New England Journal of Medicine · 2007

  2. 02

    Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

    Stanley TL, Fourman LT, Feldpausch MN, et al. · The Lancet HIV · 2019

  3. 03

    Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin

    Stanley TL, Falutz J, Marsolais C, et al. · Clinical Infectious Diseases · 2012

Inclusion of a reference does not constitute a clinical claim or recommendation.

— Go deeper

Mechanism, published research and peer-reviewed references for Tesamorelin, with no product attached.

Research review on The Assay, Merit’s editorial publication: Tesamorelin vs Sermorelin: One Approved, One Discontinued

— Common Questions

Got questions.

Is Tesamorelin FDA-approved?+

Tesamorelin is FDA-approved only as specific branded prescription drug products; research material sold as tesamorelin is not one of those products and is not FDA-approved. Supplied for research use only. Tesamorelin is named on the WADA 2026 Prohibited List under S2 as a growth hormone releasing hormone analogue and is prohibited at all times.

How is each batch of Tesamorelin tested?+

Every batch is tested by an independent laboratory for identity and HPLC purity before it is listed. Merit identifies batches by date: the current certificate for Tesamorelin 20 mg is the July 2026 batch, 99.46% purity by HPLC, published at meritsciences.com/coa/COA-2026-O4M8J4. The QR code on each vial opens the same page. Open the July 2026 batch certificate →

What does the published research on Tesamorelin show?+

In a 26-week randomized trial in 412 adults with HIV and abdominal fat accumulation (Falutz, NEJM 2007), tesamorelin reduced CT-measured visceral adipose tissue by about 15% while placebo did not. A later randomized trial (Stanley, Lancet HIV 2019) studied liver fat in HIV-associated non-alcoholic fatty liver disease. The Tesamorelin monograph at meritsciences.com/library/tesamorelin lists the references, and The Assay, Merit's editorial publication, reviews the evidence at theassay.co/articles/tesamorelin-vs-sermorelin. Read the Tesamorelin monograph →

What is Tesamorelin?+

Tesamorelin is a synthetic 44-amino-acid analog of human GHRH carrying a trans-3-hexenoic acid moiety at the N-terminus. This modification stabilizes the peptide against dipeptidyl peptidase IV (DPP-IV) cleavage, substantially extending plasma half-life relative to native GHRH and to sermorelin.

How does Tesamorelin work?+

Selective agonist at pituitary GHRH receptors. The trans-hexenoic acid modification confers DPP-IV resistance, producing longer duration of GHRH-receptor activation per dose. Downstream effects are mediated by pulsatile GH release and consequent IGF-1 generation.

What class of compound is Tesamorelin?+

Tesamorelin is classified as stabilized GHRH(1-44) analog with trans-3-hexenoic acid N-terminal modification.

What is the reported half-life of Tesamorelin?+

~25–40 min (subcutaneous administration in clinical studies).

Why does Merit ship lyophilized?+

Lyophilized (freeze-dried) material is stable in sealed storage: ≥24 months at -20°C. Peptides held in solution degrade far faster, so every compound ships as a dry powder in a sealed vial.

What does "independently assayed" actually mean?+

Every batch is tested by a laboratory independent of the facility that made it, and the certificate is published before the batch is listed. You read the same identity and purity figures we do, which is what separates Merit from a reseller catalog.

How fast does it ship?+

48 hours from order to dispatch, Monday through Thursday. UPS Ground, tracked + insured. From San Antonio, TX, most US addresses receive within 3-5 business days.

— Talk to a Pharmacologist

Question we didn't answer?

Our team answers compound and batch questions the same business day. No bots, no tickets.

Email the team →